Second line therapy in type 2 diabetes: legacy effect activation
Type 2 diabetes causes hundred thousand deaths worldwide every year. Though new antidiabetic drugs appear annually and new classes of drugs are invented approximately every ten years still a lot of type 2 diabetic patients remain to be out of the target glycemic levels. According to most of the g...
Main Author: | Ekaterina A. Shestakova |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2017-12-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://dia-endojournals.ru/dia/article/viewFile/8793/7044 |
Similar Items
-
Greater macrovascular and microvascular morbidity from type 2 diabetes in northern compared with southern China: A cross‐sectional study
by: Li Wang, et al.
Published: (2020-09-01) -
Predominant Complications of Type 2 Diabetes in Kumasi: A 4-Year Retrospective Cross-Sectional Study at a Teaching Hospital in Ghana
by: Max Efui Annani-Akollor, et al.
Published: (2019-05-01) -
Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
by: Aastha Chawla, et al.
Published: (2016-01-01) -
Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study
by: C. R. L. Cardoso, et al.
Published: (2018-02-01) -
Adenosine Deaminase- Relation with Diabetes and its Complication
by: Saqib Hyder Shah, et al.
Published: (2020-10-01)